| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| 08/06/2026 | ±2.4% | +3.8% | under-priced |
| 05/07/2026 | ±2.5% | +5.9% | under-priced |
| 02/09/2026 | ±2.5% | -1.3% | over-priced |
| 11/25/2025 | ±2.4% | +2.4% | — |
| 08/07/2025 | ±2.3% | +8.9% | under-priced |
| 05/01/2025 | ±1.7% | -18.1% | under-priced |
| 02/06/2025 | ±1.8% | -7.3% | under-priced |
| 11/27/2024 | ±1.3% | -1.0% | over-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q3 FY2026 | $1.37 | $5.0B | $377M |
| Q2 FY2026 | $-1.11 | $4.7B | $-311M |
| Q1 FY2026 | $1.34 | $5.3B | $382M |
| Q4 FY2025 | — | $5.9B | $493M |
BDX (BDX) reports in 9 days, with the next report estimated for 11/05/2026. Across the last 8 reports, options priced an average ±2.1% earnings move while the stock actually moved 6.1% on average — the market has tended to under-price BDX's earnings risk. Fundamentals into the print: EPS down 31.5% year-over-year, revenue down 9.5%. QuantLogix's live 5-factor engine currently reads BDX as a buy at 77/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →